



Photo credit: Neglected Tropical Disease Support Center

“A NEW MEDICINE IS THE PEAK OF SCIENCE AND HUMAN ENDEAVOUR. THERE IS NO GREATER GIFT THAN PROVIDING A MEDICINE TO TREAT OR PREVENT A DISEASE.”

*Mark Sullivan, AO, Founder and Managing Director, Medicines Development for Global Health*

It relieves physical pain, disability and stigmatisation; it boosts productivity, and improves economies and school attendance.

*A doctor can save thousands of lives, but a medicine can save tens of millions of lives.*

Even though we develop medicines at significantly less cost than for-profit pharmaceutical companies, *our work is still expensive*. Because there is no opportunity for a revenue stream from product sales, our challenge is to finance the work through grants, philanthropic gifts, partnerships and impact investment.

**If you would like to learn more about us and how a philanthropic gift from you could help give the gift of a new medicine to many of the poorest and most vulnerable people in the world, please visit us at <https://www.medicinesdevelopment.com/> or contact us at [philanthropy@MDGH.com](mailto:philanthropy@MDGH.com)**

Photo credit: Mapodile (iStock)

**M**ore than 1.7 billion people, over 20% of the world's population, suffer from neglected diseases. These diseases disproportionately affect the world's poorest and most underserved people, especially women and children. They cause severe sickness, disfigurement, cognitive and growth impairment, permanent blindness, social isolation, and even death.

And yet these diseases can be prevented, treated and, in many cases, eliminated.

Any one of these diseases would be deemed unacceptable if they occurred in wealthier countries, but when they affect people who cannot afford to pay, there is no incentive for industry to develop new medicines and 'market failure' takes place. Indeed, of the 1261 medicines approved by the US Food and Drug Administration in the ten years between 2010 and 2019, only 12, less than 1%, were for neglected diseases.

Medicines Development for Global Health exists precisely to address this market failure. We are a unique not-for-profit biopharmaceutical organisation and our vision is *the elimination of neglected diseases to advance global health equity*.

We are committed to developing our two medicines, moxidectin and doxramilast, to address seven neglected diseases of global importance: river blindness, lymphatic

filariasis, scabies, parasitic worm infections, leprosy type 2 reaction and tuberculosis.

River blindness, for example, is a debilitating, disfiguring and stigmatising disease caused by a worm parasite that is spread by the bite of the black fly. Symptoms include intense itching, skin depigmentation and permanent blindness. It threatens more than 200 million people, in some of the poorest regions of sub-Saharan Africa, with at least 20 million people living with active infection. The health, social and economic consequences of the disease are devastating.

We know that when these diseases are eliminated, the benefits are abundant.

